

# Editorial Note

## Editorial Note for *Santen Report 2023*

Thank you for taking the time to read *Santen Report 2023*.

The 2023 report focuses on our reforms to improve profitability and medium- to long-term growth. In particular, we focus on the new medium-term management plan under our new organization launched last September. We began reviewing our value creation process for the first time in three years in response to this new management, its strategies, and changes in the social environment. To provide a deeper understanding of the concept behind our new strategies, as well as the status of their supporting production and product creation, we included specific examples of regional expansions in commercial excellence. While prioritizing materialities, we focused our efforts on human capital from the viewpoint of sustainability. We particularly focused on human resource development and promotion. We had two Outside

- We use color palettes designed for those with low vision and other visual impairments
- We are creating Daisy audiobook versions on Sapie, a comprehensive network of information for the visually impaired (Japanese only)
- Part of the design uses winning pictures submitted in a photo contest by employees from all over the world

Directors give advice and speak at the Board of Directors and in each committee to improve the effectiveness and transparency of our governance.

Each department worked with the CEO and the management team to create content for this report. This content takes the opinions received in our dialogue with investors and stakeholders, as well as the various guidelines we have established, into account. I assure you that this integrated report was appropriately prepared and that its contents are accurate.

I hope this report will give you a sense of the challenges we face and the passion we put into our business.

### Takahiro Morita

Corporate Officer, Global Head of Core Principle & Sustainability

August 2023

<i>Santen Report 2023</i> Production Members	Investor Relations / Sustainability (Impact & Reporting) K.Itagaki, G.Sakuma, S.Akao, A.Tanaka, M.Inoue, S.Kajiya, M.Hora, K.Harada
---	--

### Editorial Policy

Santen's integrated report provides a view of overall business activities based on its CORE PRINCIPLE. The report is edited with the intention of informing stakeholders about the value Santen provides to customers and society and includes comprehensive coverage of financial information as well as non-financial information such as management strategies, review of operations and sustainability activities. Santen has streamlined content and simplified descriptions to allow for easier understanding by a wide range of stakeholders, starting with shareholders and investors. Detailed information is available on the corporate website.

### Concerning Forward-Looking Statements

This report contains forward-looking statements regarding the Company's plans, strategies and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at the time of publication. Certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this report. These risks and uncertainties include, but are not limited to, adverse economic conditions, delays in new product launches, currency exchange rates, legislative and regulatory developments.

This report contains information about pharmaceutical products (including products under development), but such information is not for the purpose of advertising or medical advice.

The following are registered trademarks of Santen's partner companies.

- Alesion (Boehringer Ingelheim KG)
- Cravit, Tarivid (Daiichi Sankyo Co., Ltd.)
- LENTIS (Teleon Holding B.V.)


### Reference Guidelines

*The International Integrated Reporting Framework* (International Integrated Reporting Council), *The GRI Sustainability Reporting Standards* (Global Reporting Initiative), *Environmental Reporting Guidelines* (Japan's Ministry of the Environment) and *Guidance for Integrated Corporate Disclosure and Company-Investor Dialogues for Collaborative Value Creation 2.0* (Japan's Ministry of Economy, Trade and Industry)



### The *Santen Report* and Santen's Information Disclosure Framework

In the *Santen Report* (this document), we publish information each fiscal year on topics that we consider particularly useful to investors. For more detailed or other relevant information, please see the Company's website.



### Detailed Information

### Applicable Scope

Santen Pharmaceutical Co., Ltd. and consolidated subsidiaries

### Reporting Period

Fiscal 2022 (April 1, 2022 to March 31, 2023). Certain information is updated after April 1, 2023.